Impact of COVID ‐19 in patients with autoimmune bullous diseases: Report from an international registry
Year: 2023
Type: article
Study design: Observational Study
Abstract: For autoimmune bullous diseases (AIBD) such as bullous pemphigoid (BP) and pemphigus an increased risk of COVID-19 infection and mortality was reported, with oral prednisolone (dose ≥10 mg/day) and treatment of rituximab being a risk factor. A population-based cohort study showed an increased COVID-19 associated mortality in patients with BP, but not in patients with pemphigus vulgaris. Here, we provide the findings of an international registry for health care providers about COVID-19 infection in patients with AIBD, reporting on timing and clinical presentation of COVID-19 infection, AIBD disease activity and outcome.
DOI: 10.1111/jdv.19242
Authors: Joost M. Meijer, Hanan Rashid, Styliani Vergadi, Emiliano Antiga, Pamela Vezzoli, Riccardo Balestri, Aikaterini Patsatsi, Soner Uzun, Dusan Skiljevic, Hana Jedlickova, Lucia Janickova, Alberto Corrà, Alessandra Ponziani, Claudia Günther, Giuseppe Cianchini, Matthias Schefzyk, Angelo Marzano, Giovanni Di Zenzo, Iakov Shimanovich, Janet Fairley, Jose M. Mascaró, Marzia Caproni, Roberto Maglie, Enno Schmidt, Barbara Horváth
Institutions: University Medical Center Groningen, University of Groningen, University of Florence, Ospedale Papa Giovanni XXIII, Aristotle University of Thessaloniki, Papageorgiou General Hospital, Akdeniz University, University of Belgrade, Univerzitetski Klinički Centar Srbije, Masaryk University, St. Anne's University Hospital Brno, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Klinik und Poliklinik für Dermatologie, Technische Universität Dresden, Ospedale Cristo Re, Medizinische Hochschule Hannover, University of Milan, Istituto Dermopatico dell'Immacolata, Istituti di Ricovero e Cura a Carattere Scientifico, University of Lübeck, University of Iowa, Hospital Clínic de Barcelona, Universitat de Barcelona
Language: English
Subfield: Dermatology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,940
OpenAlex ID: W4379966653